Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Invitae Corp (NVTA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 898,425
  • Shares Outstanding, K 74,620
  • Annual Sales, $ 68,220 K
  • Annual Income, $ -123,380 K
  • 36-Month Beta 1.82
  • Price/Sales 13.64
  • Price/Cash Flow N/A
  • Price/Book 4.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.44
  • Number of Estimates 4
  • High Estimate -0.38
  • Low Estimate -0.48
  • Prior Year -0.78
  • Growth Rate Est. (year over year) +43.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.45 +2.01%
on 12/17/18
14.71 -20.60%
on 12/04/18
-1.56 (-11.78%)
since 11/16/18
3-Month
11.45 +2.01%
on 12/17/18
18.38 -36.44%
on 09/18/18
-4.84 (-29.30%)
since 09/17/18
52-Week
4.35 +168.51%
on 03/28/18
18.38 -36.44%
on 09/18/18
+3.13 (+36.61%)
since 12/15/17

Most Recent Stories

More News
New Study Published in Journal of Clinical Oncology Supports Universal Genetic Testing for all Breast Cancer Patients

Current guidelines for genetic testing of breast cancer patients miss as many patients with pathogenic variants (or genetic mutations) as they find, according to a new study published in the Journal of...

NVTA : 11.44 (-4.98%)
Detailed Research: Economic Perspectives on United Technologies, Walmart, Invitae, Emergent Biosolutions, U.S. Physical Therapy, and Amdocs -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of United Technologies Corporation...

NVTA : 11.44 (-4.98%)
USPH : 106.68 (-2.37%)
EBS : 61.30 (+0.56%)
UTX : 116.80 (-1.68%)
DOX : 59.28 (-0.47%)
WMT : 91.18 (-0.73%)
Coherus Bioscien is Among the Companies in the Biotechnology Industry with the Best Relative Performance (CHRS , TSRO , NVTA , ABBV , AMAG )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

NVTA : 11.44 (-4.98%)
CHRS : 9.70 (-0.31%)
TSRO : 73.75 (+0.08%)
Invitae (NVTA) Reports Q3 Loss, Tops Revenue Estimates

Invitae (NVTA) delivered earnings and revenue surprises of 4.26% and 8.59%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

NVTA : 11.44 (-4.98%)
Invitae: 3Q Earnings Snapshot

SAN FRANCISCO (AP) _ Invitae Corp. (NVTA) on Wednesday reported a loss of $31.7 million in its third quarter.

NVTA : 11.44 (-4.98%)
Invitae (NVTA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NVTA : 11.44 (-4.98%)
Invitae expands work with Alnylam Pharmaceuticals to provide access to genetic testing for primary hyperoxaluria

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, announced today it has expanded its partnership with Alnylam Pharmaceuticals, the leading RNAi therapeutics company, to...

NVTA : 11.44 (-4.98%)
ALNY : 78.49 (+1.76%)
Report: Exploring Fundamental Drivers Behind Invitae, Aerie Pharmaceuticals, Gevo, Global Medical REIT, Cyclacel Pharmaceuticals, and Toll Brothers -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Invitae Corporation (NYSE:NVTA),...

TOL : 32.40 (+0.56%)
NVTA : 11.44 (-4.98%)
AERI : 38.48 (+0.68%)
GEVO : 2.45 (-3.16%)
GMRE : 8.79 (-3.19%)
CYCC : 0.81 (-3.57%)
Invitae to announce third quarter 2018 financial results on November 7, 2018

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that it will report its third quarter 2018 financial results on Wednesday, November 7, 2018 and will host...

NVTA : 11.44 (-4.98%)
Research shows high positive rate for risk of hereditary disease in study of proactive genetic health screening for healthy people

Researchers from Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, will present findings showing proactive genetic testing identifies medically significant findings for 16.5...

NVTA : 11.44 (-4.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade NVTA with:

Business Summary

Invitae Corporation is engaged in genetic diagnostics for hereditary disorders which include breast, colon and pancreatic cancer. It operates primarily in the United States, Israel and internationally. Invitae Corporation is headquartered in San Francisco, California.

See More

Key Turning Points

2nd Resistance Point 12.97
1st Resistance Point 12.50
Last Price 11.44
1st Support Level 11.73
2nd Support Level 11.42

See More

52-Week High 18.38
Fibonacci 61.8% 13.02
Last Price 11.44
Fibonacci 50% 11.36
Fibonacci 38.2% 9.71
52-Week Low 4.35

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar